Cargando…

Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy

BACKGROUND: Minimal improvements in treatment or survival of patients with osteosarcoma have been achieved during the last three decades. Especially in the case of incomplete tumor resection, prognosis remains poor. Heavy ion radiotherapy (HIT) and modern anticancer drugs like histone deacetylase in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blattmann, Claudia, Oertel, Susanne, Thiemann, Markus, Dittmar, Anne, Roth, Eva, Kulozik, Andreas E., Ehemann, Volker, Weichert, Wilko, Huber, Peter E., Stenzinger, Albrecht, Debus, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504102/ https://www.ncbi.nlm.nih.gov/pubmed/26178881 http://dx.doi.org/10.1186/s13014-015-0455-z

Ejemplares similares

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
por: Thiemann, Markus, et al.
Publicado: (2012)

Establishment of a patient-derived orthotopic osteosarcoma mouse model
por: Blattmann, Claudia, et al.
Publicado: (2015)

Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines
por: Oertel, Susanne, et al.
Publicado: (2011)

Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma
por: Blattmann, Claudia, et al.
Publicado: (2010)

Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
por: Heidler, Christopher L., et al.
Publicado: (2019)

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
por: Niehr, Franziska, et al.
Publicado: (2015)

High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma
por: Stenzinger, Albrecht, et al.
Publicado: (2013)

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
por: Fritzsche, Florian R, et al.
Publicado: (2008)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma
por: Combs, Stephanie E, et al.
Publicado: (2007)

Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma
por: Torres, Haydee M., et al.
Publicado: (2021)

Next-generation sequencing: hype and hope for development of personalized radiation therapy?
por: Tinhofer, Ingeborg, et al.
Publicado: (2015)

Evaluation of Histone Deacetylase Inhibitors as Radiosensitizers for Proton and Light Ion Radiotherapy
por: Johnson, Alicia M., et al.
Publicado: (2021)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells
por: Cain, Jason E., et al.
Publicado: (2013)

Overexpression of miR-140 Inhibits Proliferation of Osteosarcoma Cells via Suppression of Histone Deacetylase 4
por: Xiao, Qianren, et al.
Publicado: (2017)

Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data
por: Combs, Stephanie E, et al.
Publicado: (2012)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Molecular driver alterations and their clinical relevance in cancer of unknown primary site
por: Löffler, Harald, et al.
Publicado: (2016)

Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer
por: Kazdal, Daniel, et al.
Publicado: (2017)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Role of PP2Cα in cell growth, in radio- and chemosensitivity, and in tumorigenicity
por: Lammers, Twan, et al.
Publicado: (2007)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications
por: Chaiyawat, Parunya, et al.
Publicado: (2018)

Histone Deacetylase 4 Promotes Osteosarcoma Cell Proliferation and Invasion by Regulating Expression of Proliferating Cell Nuclear Antigen
por: Cao, Kun, et al.
Publicado: (2019)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

Histone deacetylase 3 regulates microglial function through histone deacetylation
por: Meleady, Laura, et al.
Publicado: (2023)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy
por: Ree, Anne Hansen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ve31j1v5eedccm6ddi8r5p9djr